SCHEMBL5630601

SCHEMBL5630601

CN1CCCC1CCNS(=O)(=O)c1ccc2c(c1)CN(CC1CC1)CC2

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 7/20 0.45
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.40
POLB P06746 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
PDE5A O76074 1/20 0.39
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
HTR6 P50406 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2400927 0.96 HRH3 (0.46) HTR7TP53TSHRHRH3ALDH1A1
SCHEMBL1241268 0.96 HRH3 (0.46) HTR7TP53TSHRHRH3ALDH1A1
Water SCHEMBL16161850 0.95 HRH3 (0.46) HTR7TP53TSHRHRH3ALDH1A1
Oxalic Acid SCHEMBL1241171 0.93 HRH3 (0.44) HTR7TP53TSHRHRH3ALDH1A1
Fumaric Acid SCHEMBL9898673 0.90 TSHR (0.41) HTR7TP53TSHRHRH3ALDH1A1
Fumaric Acid SCHEMBL9898674 0.90 TSHR (0.41) HTR7TP53TSHRHRH3ALDH1A1
Fumaric Acid SCHEMBL27987046 0.89 TSHR (0.41) HTR7TP53TSHRHRH3ALDH1A1
Fumaric Acid SCHEMBL2435682 0.89 TSHR (0.41) HTR7TP53TSHRHRH3ALDH1A1
Fumaric Acid SCHEMBL2435679 0.89 TSHR (0.41) HTR7TP53TSHRHRH3ALDH1A1
Fumaric Acid SCHEMBL9898162 0.89 TSHR (0.41) HTR7TP53TSHRHRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105834-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2007-05-10 US claimed
CN-1956962-A Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy SANOFI AVENTIS (FR) 2007-05-02 CN claimed
CN-1956962-B Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy SANOFI AVENTIS 2014-08-20 CN disclosed
US-20070105834-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2007-05-10 US disclosed
CN-1956962-A Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy SANOFI AVENTIS (FR) 2007-05-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105834-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS BACE1, SLC6A2, KCNQ2 HTR7 175/4885TP53 4291/4885TSHR 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.